Analysts Set Disc Medicine, Inc. (NASDAQ:IRON) Price Target at $119.00

Disc Medicine, Inc. (NASDAQ:IRON) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $119.00.

IRON has been the subject of several recent research reports. Morgan Stanley raised their price objective on Disc Medicine from $90.00 to $115.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Cantor Fitzgerald increased their price target on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a research note on Friday, October 17th. Raymond James Financial reissued a “strong-buy” rating and set a $117.00 price objective on shares of Disc Medicine in a research note on Monday, December 8th. Wedbush upped their price objective on shares of Disc Medicine from $90.00 to $110.00 and gave the stock an “outperform” rating in a report on Friday, October 17th. Finally, National Bankshares set a $153.00 target price on shares of Disc Medicine in a report on Friday, October 17th.

Disc Medicine Stock Performance

Shares of IRON opened at $80.33 on Friday. The company has a 50-day simple moving average of $88.21 and a two-hundred day simple moving average of $69.82. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45. The firm has a market capitalization of $3.03 billion, a PE ratio of -15.01 and a beta of 0.87. Disc Medicine has a one year low of $30.82 and a one year high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, analysts anticipate that Disc Medicine will post -4.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Jonathan Yen-Wen Yu sold 30,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $84.70, for a total value of $2,541,000.00. Following the transaction, the chief operating officer owned 40,555 shares in the company, valued at $3,435,008.50. The trade was a 42.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William Jacob Savage sold 13,093 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the sale, the insider directly owned 75,702 shares in the company, valued at $6,905,536.44. This trade represents a 14.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 451,555 shares of company stock worth $38,742,458 over the last three months. 3.64% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Disc Medicine by 22.2% in the 1st quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company’s stock worth $64,782,000 after acquiring an additional 236,800 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Disc Medicine by 18.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 194,725 shares of the company’s stock worth $9,666,000 after purchasing an additional 29,653 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Disc Medicine by 11.5% during the first quarter. Swiss National Bank now owns 35,900 shares of the company’s stock valued at $1,782,000 after purchasing an additional 3,700 shares in the last quarter. Invesco Ltd. boosted its position in shares of Disc Medicine by 27.1% during the first quarter. Invesco Ltd. now owns 13,834 shares of the company’s stock valued at $687,000 after buying an additional 2,953 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Disc Medicine in the 1st quarter worth about $5,595,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.